KORU Medical Systems Inc

KORU Medical Systems Inc(KRMD)股票分析

$3.030

-0.222 (-7.34%)收盤時

Loading chart…
最高
3.310
開盤
3.310
成交量加權均價
3.09
成交量
143.77K
市值
130.43M
最低
2.920
成交金額
443.78K
企業價值/稅息折舊攤銷前利潤(TTM)
36.88

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

AI 分析 of KORU Medical Systems Inc (KRMD)

買進

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

估值指標

KORU Medical Systems Inc(KRMD)目前預期本益比為 76.34,5 年平均預期本益比為 -7.42。

預期本益比

合理
5 年均值 P/E
-7.42
目前P/E
76.34
高估
108.26
低估
-123.09

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-24.07
目前EV/EBITDA
36.88
高估
59.60
低估
-107.75

預期股價營收比

低估
5 年均值 P/S
4.07
目前P/S
2.53
高估
5.09
低估
3.05

Alphio AI 對 KRMD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%KRMD

$3.23

情境價格

基

基準

基準 · 50%KRMD

$2.98

情境價格

悲

悲觀

悲觀 · 25%KRMD

$2.84

情境價格

持有 KRMD 的大戶

F

First Light Asset Management, LLC

+ 持有KRMD

+0.00%

3個月報酬率

事件時間軸

2026-08-05 (ET)

17:30:00

Company Reiterates Positive EBITDA Outlook for FY26

17:30:00

Koru Reports Q2 Revenue of $12.0M, Exceeding Expectations

2026-05-06 (ET)

16:20:00

Koru Medical Affirms FY26 Revenue View of $47.5M-$50M

16:20:00

Koru Medical Reports Q1 Revenue of $11.77M

2026-03-12 (ET)

16:40:00

KORU Medical Reports Q4 Revenue of $10.9M

資訊

KRMD 常見問題 —— 由 Alphio AI 解答

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易